# OnCo record btk-c481s (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/btk-c481s/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "btk-c481s" ;
  schema:name "BTK resistance mutations: C481S, and L528W and T474I after the non-covalent inhibitors"@en ;
  schema:alternateName "BTK C481S"@en, "BTK Cys481Ser"@en, "BTK L528W"@en, "BTK T474I"@en, "BTK resistance mutation"@en, "ibrutinib resistance mutation"@en ;
  schema:description "A change in the enzyme BTK at the exact point where the drug grips it. The enzyme keeps working and the drug no longer holds, which is the usual reason a BTK inhibitor stops working after it has been working well."@en ;
  schema:url <https://onco.cc/biomarkers/btk-c481s/> ;
  schema:dateModified "2026-09-30"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1400029>, <https://doi.org/10.1182/bloodadvances.2022008325>, <https://doi.org/10.1056/NEJMoa2300696> ;
  onco:tag "biomarker", "resistance", "lymphoma" ;
  onco:related <https://onco.cc/biomarkers/bcl2-g101v/> ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/plcg2/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/>, <https://onco.cc/pathways/resistance-routes-map/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/cross-resistance/>, <https://onco.cc/terms/ngs/> .